BioSpace News Archive

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 41,800 shares of the Company’s common stock at an exercise price per share of $37.56, which was the closing price on January 10, 2022.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced certain unaudited preliminary fourth quarter and full-year 2021 revenue results.

CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results, Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022.

Asia Green Biotechnology Corp. announced that it has closed the previously announced financing arrangement with a director of the Company.

Geneva, Switzerland,January 11, 2022 - Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that CEO, Tim Dyer, will present at the Swiss Equities Baader Virtual Conference taking place January 12 - 14th, 2022.

Prescription drop can correct common vision problem plaguing half of the U.S. adult population.

Sana Biotechnology, Inc. announced that the company entered into an agreement with the National Cancer Institution, an institute of the National Institutes of Health, for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking.

Inivata, a leader in liquid biopsy, today announced that it has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC).